Product Datasheet

MK-1084


Catalog No. **BP-00334** · CAS **2641216-67-1** · Form **free base** · Physical state **other** · Color **white to off-white** · Version **1.0** · Revision **2026-11-04**

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target	Research area
Ras	**Cancer**

Molecular formula	$C_{32}H_{31}ClF_2N_6O_4$
Molecular weight	**637.0760**

STRUCTURE



DESCRIPTION

MK-1084 is a selective KRAS G12C inhibitor that is currently in Phase I clinical trial (NCT05067283). MK-1084 exhibits anticancer activity and can be used either alone or in combination with pembrolizumab for cancer research.

BIOLOGICAL ACTIVITY

Calderasib (MK-1084) (0.01-10 μM, 2 h) inhibits the SOS-catalyzed nucleotide exchange with IC50 of 1.2 nM, inhibits the phosphorylation of ERK1/2 in cell H358 with IC50 of 9 nM

SOLUBILITY

Soluble in DMSO

In vitro	DMSO : 100 mg/mL

REFERENCES

[1]. Rojas C, et al. 663P Safety and preliminary efficacy of the KRAS G12C inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC[J]. Annals of Oncology, 2023, 34: S466-S467.

[2]. Ma X, et al., Discovery of MK-1084: An Orally Bioavailable and Low-Dose KRASG12C Inhibitor. J Med Chem. 2024 Jul 11;67(13):11024-11052.